We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology serving patients in 100+ countries with the help of our employees ... Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology serving patients in 100+ countries with the help of our employees in areas including Clinical Affairs Quality Engineering Research & Development Regulatory Affairs Sales & Marketing corporate functions and more. Our roots date back to 1958 when Miles Lowell Edwards a retired engineer with a background in hydraulics and fuel pump operations set out to build the first artificial heart. Edwards believed the heart could be mechanized and was encouraged by Dr. Albert Starr to focus on developing an artificial heart valve. After just two years the first Starr-Edwards mitral valve was developed and successfully placed in a patient. This innovation spawned Edwards Laboratories. Show more
Company announces $1 billion share repurchase Edwards Lifesciences (NYSE: EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE:...
Please replace the release with the following corrected version. The updated release reads: FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES Edwards...
Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve...
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.81 | -2.63694638695 | 68.64 | 71.7 | 65.5 | 9628227 | 67.59009566 | CS |
4 | -3.87 | -5.4738330976 | 70.7 | 71.7 | 64.7 | 7289354 | 67.91595534 | CS |
12 | -23.47 | -25.9911406423 | 90.3 | 95.25 | 58.93 | 6438830 | 68.43791257 | CS |
26 | -27.1 | -28.851272224 | 93.93 | 96.12 | 58.93 | 4488350 | 75.22332294 | CS |
52 | -2.52 | -3.63374188897 | 69.35 | 96.12 | 58.93 | 4458913 | 75.47921328 | CS |
156 | -53.53 | -44.4749086075 | 120.36 | 131.73 | 58.93 | 3571037 | 84.62644287 | CS |
260 | -152.45 | -69.5229843123 | 219.28 | 248.5 | 58.93 | 2994504 | 93.86871035 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions